Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (14)	2/9/2002 12:46:34 PM
From: tuck	Read Replies (3) \| Respond to of 510

Nigel, Nice dig! That's why I like GenomeWeb; you sometimes get a useful clue like that, that does not show up in the standard wire stories. I think CIPH is the Affymetrix of proteomics. It may not be the best, but it's the first. It has an installed base that is being used in exciting work like this. While competitors are still not quite launched, CIPH's chips are starting to show up in abstracts under the "Materials & Methods" heading. Just like Affymetrix. And like AFFX, it has a little cloud of litigation over its head which can hopefully be resolved without a long, drawn out legal battle that is only really won by the arms dealers (i.e. the lawyers). It is because of this attitude that BLUE HP has not swing traded CIPH, but is simply holding it. From the BIO interview, the following comment from Dr. Liotta gives us a potentially important clue with respect to timing of sales . . . >>In addition, we are developing a whole series of future confirmatory trials in multiple institutions and with cooperative groups to test this as an early diagnostic tool over a larger population. It should take about six months to initiate all these trials.<< Cheers, Tuck